Introduction
Acute liver failure (ALF, sometimes referred to as fulminant hepatic failure) is a severe liver disease characterized by encephalopathy and coagulopathy in patients with previously normal liver function [
1‐
3]. There is no effective therapy for ALF other than liver transplantation. In China, ALF is a serious consequence of the acute exacerbation of hepatitis B virus (HBV) infection. To some extent, the ALF has been created by an animal model induced by the co-injection of
d-galactosamine (
d-GalN) and lipopolysaccharides (LPS), which has been widely used to examine the mechanisms underlying ALF [
4,
5].
GSK3 is a ubiquitously expressed serine/threonine kinase that is initially found to regulate glycogen synthesisThere are two highly homologous isoforms, GSK3α and GSK3β. Originally identified in mammals as a cytoplasmic modulator of glycogen metabolism, GSK3β is now recognized as a central regulator of cellular events, including cell fate determination, microtubule function, cell cycle regulation, apoptosis, and inflammatory responses [
6‐
11]. Our previous study showed that GSK3β is activated in the progression of ALF induced by
d-GalN/LPS, and moreover, GSK3β inhibition can ameliorate hepatotoxicity in ALF mice [
12], while its regulatory mechanism is very poorly understood.
Oxidative stress is a condition in which the cellular levels of reactive oxygen species (ROS) exceed the neutralizing capacity of antioxidants. Injurious oxidant stress, therefore, may result from either the excessive production of ROS, or a diminution in antioxidant levels, and a combination of these two effects [
13,
14]. Oxidative stress is common in various types of liver injury, and plays a critical role in the mechanism of ALF [
15]. Recent studies have revealed that oxidative stress may also regulate cell death by altering GSK3β activity. For instance, a critical role of GSK3β is found in mediating the oxidative stress-induced neuronal cell death [
16‐
19]. The stress-induced GSK3β regulates the redox stress response by phosphorylating glucose-6-phosphate dehydrogenase, as demonstrated in arabidopsis [
20].
Given the notion that oxidative stress can regulate the GSK3β pathway to promote the cell apoptosis, we hypothesized that oxidative stress-GSK3β may be play a important role in the mechanism of d-GalN/LPS-induced ALF. To test this hypothesis, we performed experiments to evaluate the oxidative stress during the progression of ALF, to investigate GSK3β inhibition in regulating oxidative stress through both the in vivo and in vitro models. Moreover, to confirm their clinical relevance, we further evaluated the activity of GSK3β in ALF induced by HBV infection.
Methods
Animals and treatment
Male wild-type (WT, C57BL/6) mice (8–12 weeks of age) were purchased from Capital Medical University (Beijing, China) and housed in the Capital Medical University animal facility under specific pathogen-free conditions, and received humane care according to Capital Medical University Animal Care Committee guidelines. To induce ALF, the mice were injected intraperitoneally with d-GalN (700 mg/kg, Sigma, St Luis, MO) and LPS (10 μg/kg, Invivogen, San Diego, CA). Mice were treated with a single dose of freshly prepared N-acetylcysteine (NAC, at 300 mg/kg, by i.p. injection, Sigma, St Luis, MO), a ROS scavenger, immediately after d-GalN/LPS treatment. In some experiments, SB216763 (25 mg/kg, Sigma, St Luis, MO) dissolved in dimethyl sulfoxide (DMSO), a specific inhibitor for GSK3β, was suspended in phosphate-buffered saline (PBS) and administered intraperitoneally 2 h prior to d-GalN/LPS treatment. Mice were sacrificed at various time-points after d-GalN/LPS treatment; liver and serum samples were collected for future analysis.
Serum aminotransferase activities
Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as markers of hepatic damage, were measured by using a multiparameteric analyzer (AU 5400, Olympus, Japan), according to an automated procedure.
Assay of ROS level in liver
To determine the level of ROS in the liver tissue, liver homogenates were made in lysis buffer and analyzed using a chemical fluorescent ROS assay kit (Jiancheng Bio, Nangjing) according to the manufacturer’s instruction, which is based on the oxidation of 2′7′-dichlorodihydrofluorescein diacetate to 2′7′-dichloro-fluorescein.
Assay of MDA,GSH and SOD in liver
A part of liver tissue was prepared for homogenization with a buffer containing 0.15 M KCl to obtain 1:10 (w/v) homogenates. The homogenates were then centrifuged at 12,000×
g (4 °C) for 20 min to collect the supernatants. The concentrations of malondialdehyde (MDA), and glutathione (GSH), as well as superoxide dismutase (SOD) activities were measured, as described previously [
21].
Cell cultures
Human hepatocyte line HL-7702 (Xiangfu Biological Company, Shanghai) was plated in 48-well or 6-well plates at an appropriate density. After overnight culturing, hydrogen peroxide (H2O2, 1 mmol/L, Habo Company, Shanghai) or antimycin A (2 μg/ml, Sigma, St Luis, MO) was added into the culture wells. To study the effects of GSK3β inhibition on hepatocyte apoptosis induced by oxidative stress, SB216763 (10 mΜ) was added 2 h prior to the H2O2 or antimycin A treatment. Cell apoptosis was evaluated at 12 h by caspase western blots and lactate dehydrogenase (LDH) assay (Biochain Institute, Hayward, CA) of culture supernatants, according to the manufacturer's instructions.
Western blot analysis
Protein was extracted from liver tissue with RIPA buffer with phosphatase inhibitors and protease inhibitors. Proteins in sodium dodecyl sulfate (SDS)-loading buffer were subjected to SDS-12 % polyacrylamide gel electrophoresis (PAGE) and transferred to polyvinylidene difluoride (PVDF) membrane. Monoclonal rabbit antibodies against p-GSK3β, total GSK3β, p-JNK, total JNK, Cyt c, caspase-3, cleaved caspase 3 and β-actin (Cell Signaling Technology, Santa Cruz, CA) were used at 4 °C overnight. Then the membrane was treated with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody. The relative quantities of proteins were determined by a densitometer and expressed as absorbance units (AU).
Immunofluorescence staining
Paraffin sections were treated with xylene for three times with 10 min each time. The sections were hydrated through a graded alcohol series and then rinsed three times with distilled water. The slides were incubated for 20 min in 10 % goat serum in PBS and then p-GSK3β rabbit monoclonal antibody (Cell Signaling Technology, Santa Cruz, CA) overnight at 4 °C. The slides were incubated with Alexa Fluor® 568 goat anti-rabbit IgG (1:200, Invitrogen, Grand Island, NY) for 45 min. After three washings with PBS, the nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI, 1 μg/ml, Shizebio, Shanghai) for 10 min. The images were examined on a Nikon Eclipse E800 fluorescent microscope.
Determination of hepatic GSK3β activity
To determine the activity of GSK3β in the liver tissue, liver homogenates were made in lysis buffer and analyzed using a colorimetric GSK3β assay kit (Jianglaibio Co, Shanghai) according to the manufacturer’s instructions.
Human liver samples
This study meets the ethical guidelines of the 1975 Declaration of Helsinki and the study protocol was permitted by the Medical Ethics Committee of Beijing YouAn Hospital. Informed consent was obtained from all patients. Human liver tissue was obtained from the normal subjects, chronic hepatitis B (CHB) patients and HBV-induced ALF patients. All patients were hospitalized during 2009–2011 at Beijing YouAn Hospital. Clinical characteristics and details of clinical data of the patients in analysis are shown in Table
1.
Table 1
General clinical characteristics of the different study groups
Age (years) | 39.4 ± 3.6 | 32.4 ± 4.1 | 41.6 ± 5.3 | 0.11 |
Gender (male/female) | 6/2 | 7/5 | 8/4 | 0.437 |
Alanine aminotransferase (U/L) | 35.1 ± 6.1 | 93.3 ± 18.3 | 210.4 ± 76.3 | 0.026 |
Aspartate aminotransferase (U/L) | 30.6 ± 3.9 | 62.6 ± 15.4 | 305.8 ± 44.6 | 0.038 |
Serum bilirubin (μmol/l) | 8.8 ± 2.9 | 20.9 ± 6.3 | 196.1 ± 50.6 | 0.01 |
Prothrombin time (s) | 9 ± 2.4 | 15 ± 5.2 | 34.4 ± 7.2 | 0.022 |
Albumin (g/L) | 46.2 ± 6.9 | 32.6 ± 10.8 | 26.7 ± 5.7 | 0.039 |
Creatinin (μmol/L) | 73.6 ± 21.5 | 80.1 ± 29.0 | 95.4 ± 32.8 | 0.042 |
Hepatic encephalopathy score | − | − | 1.7 ± 0.3 | − |
Child-Pugh score | − | 6 ± 0.6 | 13.7 ± 2.4 | 0.031 |
Model for end-stage liver disease score | − | − | 28.2 ± 4.2 | − |
HBsAg test | − | Positive | Positive | − |
Statistical analysis
Results are shown as mean ± SD. The data were analyzed with statistics software SPSS 11.5 using a nonparametric analysis of variance test. Differences were considered significant if the P value was less than 0.05.
Discussion
The main findings in this study were that oxidative stress played a critical role in the mechanism of ALF, and oxidative stress inhibition by NAC ameliorated the toxin induced liver failure. Importantly, the present study highlighted a novel role of GSK3β in response to oxidant stress in ALF. GSK3β inhibition blocked
d-GalN/LPS-induced oxidative stress and was capable of reducing the hepatocyte apoptosis induced by oxidant stress. Therefore, our findings suggest that oxidant stress exacerbates hepatotoxicity in ALF via increasing GSK3β activity (as shown by Fig.
6d).
Oxidative stress is commonly associated with a number of liver diseases, and is thought to play a role in the pathogenesis of ALF [
27,
28]. Oxidative stress is a condition in which the cellular levels of ROS exceed the neutralizing capacity of antioxidants [
15]. The effects of oxidative stress are balanced by antioxidant activities involving a variety of enzymatic and non-enzymatic mechanisms. Active oxygen scavenging systems include enzymes such as SOD, glutathione peroxidase (GSH-P
X) and catalase, and non-enzymatic antioxidants including GSH, vitamin C, and vitamin E, etc. [
29]. Our results have shown that the activities of SOD and GSH in ALF are significantly lower than the normal control, which are negatively correlated with serum ALT and AST levels. Furthermore, the concentration of MDA, which is used as an important indicator of oxidation, was significantly higher than normal values. With the progression of ALF, the status of oxidation is increased, and conversely, the antioxidants gradually reduced, which results in an imbalance of oxidation over anti-oxidation, and the severe oxidative stress in the occurrence of ALF and further progression of liver injury.
Oxidative stress regulates hepatocyte injury and death by altering signal transduction pathways. Studies have shown that ROS may also activate cellular signal pathways, such as mitogen-activated protein kinase (MAPK), nuclear factor-κB (NF-κB), phosphatidylinositol 3-kinase (PI3K), p53, and β-catenin/Wnt, etc. [
15,
30‐
33]. Our study found that GSK3β is a new fulcrum to regulate oxidative stress in ALF. GSK3β is constitutively active in resting cells to a proper extent. GSK3β activity is depressed at an early stage and subsequently returns to a high level in the ALF, which suggests the activity of GSK3β is precisely mediated in the progression of ALF and plays a complicated role in the pathogenesis of ALF. In vitro, oxidative stress activates GSK3β, and GSK3β inhibition significantly alleviates the hepatocyte apoptosis induced by oxidative stress. So, it can be speculated that GSK3β is one of the regulatory molecules of the oxidative stress signaling pathway. In vivo, our results show that the NAC inhibits oxidative stress to protect liver from
d-GalN/LPS-induced acute injury in mice, which is in line with the reduced the activity of GSK3β. These results further prove that GSK3β is one of the key regulatory molecules in the balance of oxidation/antioxidant. In summary, we conclude that the balance of oxidation/antioxidant is tilted in the progression of ALF; the oxidation process is in a dominant position because of changes of GSK3β activity, which result in oxidative stress promoting liver injury in ALF. Thus, inhibition of GSK3β activity can reverse the imbalanced oxidation in liver tissue, and GSK 3β is a fulcrum to regulate oxidative stress in ALF.
Previous study had demonstrated that HBV infection increased phosphor ser-9-GSK3β and decreased the GSK3β activity in the Huh7 cell line, which could deliver a replication competent HBV genome [
34]. Our studies further explored the issue and showed that GSK3β activity is slightly suppressed in the CHB patients, while it is up-regulated in the ALF patients with HBV infection. It can be speculated that the replication of HBV is in a dominant position and the balance of oxidation/antioxidant has not yet been broken in the patients with chronic hepatitis. At this period, anti-oxidation is in an advantageous position and the activity of GSK3β is affected by HBV. But for ALF patients, the oxidation is in an increasingly dominant position, and oxidative stress may contribute to the increased activity of GSK3β, therefore, either in the
d-GalN/LPS-induced ALF model, or in the HBV-induced ALF patients, GSK3β activity is elevated in all. Based on the findings, we speculate that GSK3β activity can be measured to predict the prognosis of HBV infection for the breakthrough and persistence. The in-depth research in these regards is needed as future work.
We need to further clarify that, in hepatitis B virus (HBV) infection, hepatocyte injury is triggered by immune-mediated apoptosis and continues as a nonspecific necroinflammatory response. Necroinflammation of the liver produces excessive oxidative stress leading to further hepatocyte damage. Although oxidative stress plays important roles in HBV-related liver injury, clinically it is not the only factor of hepatotoxicity in CHB. Decrease of GSK3β activity in the liver tissues of CHB patients may be related to a protective response against oxidative stress or inflammatory pressure caused by immune cytotoxicity, as well as HBV itself. Moreover, GSK3β activity may be also regulated by glucose metabolism including glycogen synthesis or insulin interaction under liver injury. Thus, oxidative stress is not the only way to regulate the activity of GSK3β.
In summary, oxidative stress-activated GSK3β may be one of the mechanisms governing the pathological basis for ALF, and GSK3β inhibition represents a potent strategy to suppress oxidative stress, and ameliorate liver pathology. Further preclinical studies with GSK3β inhibitors are warranted to pave the way for the development of a clinically applicable therapeutic strategy against ALF.
Acknowledgments
This work was supported by the China National Key Project of the Twelfth Five-year Plan (2012ZX10002004-006, 2012ZX10004904-003-001, 2013ZX10002002-006-001), the National Natural Science Foundation of China (81270532, 81372094,81300349), the Beijing Excellent Talents Training Funding (2011D003034000022), the Technology Foundation for Selected Overseas Chinese Scholars, Ministry of Personnel of Beijing (2012), and Applied Research for the Clinical Characteristics of Capital (Z121107001012167).